About Avalon Pharma
Avalon Pharma is a publicly listed company based in Riyadh (Saudi Arabia) founded in 1998 by Ahmad S Al Tabbaa, and was acquired by Timeline Logistics in October 2008. Small molecules for cancer therapeutics are manufactured and developed. Its chief executive, as recorded, is Mohamed Maher Al Ghannam. Its website avalonpharmaceutical.com draws about 27 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals and Drugs.
Company details
Manufacturer of small molecules for cancer therapeutics. It is a biopharmaceutical company, focuses on the discovery, development, and commercialization of cancer therapeutics. Uses its proprietary AvalonRx technology. Lead product candidate includes, AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, is in Phase IIa clinical development for the treatment of hematologic and solid cancers. Has drug discovery, development, and commercialization agreement with Merck Co. to identify and develop inhibitors of a selected target in the area of oncology. Holds a collaboration and license agreement with MedImmune for the discovery of small molecule therapeutic compounds in the area of inflammatory disease. A collaboration agreement with ChemDiv for the discovery and development of small molecule oncology therapeutics; a collaboration with Medarex to jointly research, develop, and commercialize human antibodies against the companys cancer targets; and an agreement with Novartis Institutes for Biomedical Research for the discovery of small molecule therapeutic compounds.
- Headquarters Riyadh, Saudi Arabia
- Founders Ahmad S Al Tabbaa
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website avalonpharmaceutical.com
- Social LinkedIn X
- Acquired by Timeline Logistics (Oct 2008)
- Legal Name Middle East Pharmaceutical Industries Company
- Annual Revenue$460.48 M16.87as on Dec 31, 2025
- Net Profit$97.01 M21.49as on Dec 31, 2025
- EBITDA$128.35 M21.41as on Dec 31, 2025
- Investors
- Acquired byTimeline Logistics
(Oct 2008)
Investors in Avalon Pharma
Avalon Pharma has secured backing from 1 investor. Prominent investors backing the company include Timeline Logistics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Timeline Logistics is engaged in providing delivery and warehousing services in Texas. | 2005 | timelinelogistics.com | Houston, United States |
Investor details for Avalon Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avalon Pharma
3 people are tracked at Avalon Pharma (3 in leadership).
| Name | Role | Group |
|---|---|---|
Ahmad S Al Tabbaa | Founder & Chairman | Leadership |
Mohamed Maher Al Ghannam | CEO & Managing Director | Leadership |
Moazam A. Shah | Chief Financial Officer | Leadership |
Complete people profiles for Avalon Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Avalon Pharma
Avalon Pharma is a publicly listed company on the TADAWUL with ticker symbol 4016 in Saudi Arabia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Feb 2024
- Listed onTADAWUL: 4016
- Listed entityMiddle East Pharmaceutical Industries Company
- Exchange sectorHealth technology
- ISINSA160G51UO10
- Share price61.90 SAR · 2026-10-14
- Market capitalisation2,166,500,053.00 SAR
- Price to earnings20.0
- EPS (diluted, trailing year)3.10 SAR
- Dividend yield2.49%
- Volume (last session)490
Financials of Avalon Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 460.5M SAR | 97.0M SAR | 128.3M SAR |
| 2024 | 394.0M SAR | 79.8M SAR | 105.7M SAR |
| 2023 | 338.4M SAR | 65.8M SAR | 90.6M SAR |
| 2022 | 302.7M SAR | 59.5M SAR | 81.0M SAR |
| 2021 | 287.2M SAR | 66.3M SAR | 86.1M SAR |
Detailed financial statements for Avalon Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Avalon Pharma
3 dated milestones of Avalon Pharma across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Avalon Pharma is founded.
- Exit Acquired by Timeline Logistics.
- IPO Lists on the stock exchange (IPO).
Web traffic of Avalon Pharma
The website of Avalon Pharma (avalonpharmaceutical.com) receives about 26.9K visits a month and ranks #1,709,094 among all websites worldwide, #2,314 in Biotechnology and Pharmaceuticals.
- Monthly visits26.9K
▲ 54.3% vs previous month
- Unique visitors5.2K
per month
- Global rank#1,709,094
among all websites
- Category rank#2,314
Health · Biotechnology and Pharmaceuticals
- Bounce rate56%
- Pages per visit1.8
- Average visit27 sec
- DevicesDesktop 14% · Mobile 86%
Websites whose visitors overlap most with Avalon Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| yashpharma.com | 100% | View details | |||
| sajapharma.com | 100% | #2,534,807 | View details | ||
| mspharma.com | 98% | 12.4K | #1,443,733 | View details | |
| hikma.com | 98% | 159K | #227,704 | View details | |
| fiercebiotech.com | 79% | 858.3K | #81,022 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Avalon Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avalon Pharma
Complete news archive for Avalon Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avalon Pharma
Avalon Pharma was founded in 1998.
Avalon Pharma is headquartered in Riyadh, Saudi Arabia.
Mohamed Maher Al Ghannam is the CEO of Avalon Pharma, as recorded in our data.
Manufacturer of small molecules for cancer therapeutics. It is a biopharmaceutical company, focuses on the discovery, development, and commercialization of cancer therapeutics. Uses its proprietary AvalonRx technology. Lead product candidate includes, AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, is in Phase IIa clinical development for the treatment of hematologic and solid cancers. Has drug discovery, development, and commercialization agreement with Merck Co. to identify and develop inhibitors of a selected target in the area of oncology. Holds a collaboration and license agreement with MedImmune for the discovery of small molecule therapeutic compounds in the area of inflammatory disease. A collaboration agreement with ChemDiv for the discovery and development of small molecule oncology therapeutics; a collaboration with Medarex to jointly research, develop, and commercialize human antibodies against the companys cancer targets; and an agreement with Novartis Institutes for Biomedical Research for the discovery of small molecule therapeutic compounds.
Yes, Avalon Pharma is publicly traded on TADAWUL under the ticker symbol 4016.
Avalon Pharma has 1 investor. Key investors include Timeline Logistics.
Yes. Avalon Pharma was acquired by Timeline Logistics in October 2008.